BGCI

About This Project

Malignant diseases represent a major health problem in all parts of the world and their incidence, according to the WHO/IARC World Cancer Report 2014, will increase by 57% worldwide in the next 20 years. Standard treatment strategies for cancer including surgery, chemotherapy and targeted molecular therapy still do not guarantee complete elimination of the disease. Conventional chemotherapy drugs work efficiently only during the time of administration. Over 50% of chemotherapy patients experience cancer relapse within months or years. Chemotherapy damages healthy cells and side effects include nausea, vomiting, pain, fatigue, mouth and throat sores, internal bleeding, and anaemia, as well as compromising the immune system.

 

BIRD-C have developed Bacterial Ghost Cancer Immunotherapy (BGCI) – a novel personalised medicine approach towards vaccination against tumours. BIRD-C’s therapeutic cancer vaccines are based on personalised dendritic cells-based cancer immunotherapy that targets the tumour microenvironment using Bacterial Ghosts (BGs), the proprietary platform technology of BIRD-C.

 

The tumour therapy strategy is to (re)stimulate the immune system to revert the tumour evasion and build strong humoral and cellular immune responses against patient-specific tumour antigens. Obtained results show that BGCI can generate effective response to tumours and indicate novel prospective methods for cellular cancer immunotherapy.

 

By exposing specific tumour molecules on their surface, BGs are able to elicit a selective immune response against target cancer molecules that eventually induce the death only of the tumour cells. By remaining non-toxic to cells that do not express the specific cancer cells, this therapy results in dramatically reduced side-effects. As a result the patient immune system is strengthened and able to better respond to cancer treatments

 

This approach has been tested in a form of advanced personalised cancer therapy and has improved the survival of patients with solid tumours.

Topic
PHC-12 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Year

2016

Cutoff

September

Beneficiaries

Coordinator

BIOTECH INNOVATION RESEARCH DEVELOPMENT AND CONSULTING GMBH & CO KG

Country

Austria